The GOI program targets U.S.-based startups working on technologies such as antibodies, peptides, small molecules, formulations, and cell and gene therapies, with applications open until September 30, 2025, and a multi-stage selection process involving document review, technology assessment, and presentations.

Celltrion, founded in 2002, is a leading South Korean biotech firm known for developing biosimilars like Remsima and Herzuma, and employs around 3,003 staff as of mid-2025, supporting startups through open innovation and extensive industry expertise.

Seoul Bio Hub and Celltrion have launched the '2025 Seoul Bio Hub-Celltrion Global Open Innovation (GOI)' program to support U.S. biotech startups, established within the past seven years, in entering the Asian market, with applications open until September 30, 2025.

South Korea's biopharmaceutical sector is valued at around $22 billion, ranking 13th globally, and is projected to grow to $81.6 billion by 2030 at an annual rate of 18.3%, driven by active private investments and robust R&D efforts.

The country is also a leader in clinical trials, with Seoul ranking highly worldwide, supported by government policies aiming to secure a top-three position globally by 2027.

Selected startups will receive tailored support and opportunities for global expansion through collaboration with Celltrion, leveraging Seoul's advanced clinical and research infrastructure.

Since its establishment in 2017, Seoul Bio Hub has supported over 120 startups with shared lab facilities and research infrastructure, attracting significant follow-up investments totaling 576 billion KRW.